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Abstract
Background: Sedatives and analgesics are administered to provide sedation and manage agitation and pain in
most critically ill mechanically ventilated patients. Various sedation administration strategies including protocolized
sedation and daily sedation interruption are used to mitigate drug pharmacokinetic limitations and minimize
oversedation, thereby shortening the duration of mechanical ventilation. At present, it is unclear which strategy is
most effective, as few have been directly compared. Our review will use network meta-analysis (NMA) to compare
and rank sedation strategies to determine their efficacy and safety for mechanically ventilated patients.
Methods: We will search the following from 1980 to March 2016: Ovid MEDLINE, CINAHL, Embase, PsycINFO, and
Web of Science. We will also search the Cochrane Library, gray literature, and the International Clinical Trials Registry
Platform. We will use a validated randomized control trial search filter to identify studies evaluating any strategy to
optimize sedation in mechanically ventilated adult patients. Authors will independently extract data from eligible
studies in duplicate and complete the Cochrane Risk of Bias tool. Our outcomes of interest include duration of
mechanical ventilation, time to first extubation, ICU and hospital length of stay, re-intubation, tracheostomy,
mortality, total sedative and opioid exposure, health-related quality of life, and adverse events. To inform our NMA,
we will first conduct conventional pair-wise meta-analyses using random-effects models. Where appropriate, we will
perform Bayesian NMA using WinBUGS software.
Discussion: There are multiple strategies to optimize sedation for mechanically ventilated patients. Current ICU
guidelines recommend protocolized sedation or daily sedation interruption. Our systematic review incorporating
NMA will provide a unified analysis of all sedation strategies to determine the relative efficacy and safety of
interventions that may not have been compared directly. We will provide knowledge users, decision makers, and
professional societies with ranking of multiple sedation strategies to inform future sedation guidelines.
Systematic review registration: PROSPERO CRD42016037480
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Background
Sedatives and analgesics are administered in 60–90 % of
critically ill patients to manage agitation, reduce pain,
and facilitate mechanical ventilation [1–4]. Despite their
widespread use, accumulating data indicate these drugs
may prolong mechanical ventilation [1, 5–14] and in-
crease delirium [15, 16], long-term cognitive impair-
ment [8, 15], and mortality [10–13]. In this analysis, we
will provide a ranking of multiple strategies used to
optimize sedation in mechanically ventilated patients to
inform future sedation guidelines.
The provision of optimal sedation in critically ill patients
is challenging for a number of reasons, including fluctuat-
ing illness acuity, the presence of delirium and other
disease-associated brain dysfunction (e.g., encephalopathy),
pre-morbid psychiatric disorders, and risk of drug or alco-
hol withdrawal. In addition, multi-organ dysfunction and
polypharmacy can render drug pharmacokinetics and dy-
namics unpredictable, increasing the risk for adverse events
and drug interactions. Given these complexities, an ideal
sedative or analgesic for critically ill patients would include
minimal drug accumulation, ease of titration, tolerable
adverse effects, and a clean drug interaction profile (i.e.,
avoidance of cytochrome P450 metabolism), all at a reason-
able cost. At this time however, no sedative or analgesic drug
satisfies all these criteria. Despite this, drug administration
strategies exist that attempt to mitigate the pharmacokinetic
limitations of available drugs; the most common approaches
include daily sedation interruption, nurse-directed protoco-
lized sedation, analgesia-based sedation or no sedation, and
intermittent dosing versus continuous infusions.
Daily sedation interruption is defined as a short-term sus-
pension, hold, discontinuation, or cessation of intravenous
sedative or in some cases, analgesic medication [13]. This
approach is used to allow elimination or prevent accumula-
tion of drug, promote patient wakefulness to gauge toler-
ance for complete cessation of sedation and/or liberation
from invasive mechanical ventilation, and where necessary,
identify the smallest effective dose of drug to be used. Pro-
tocolized sedation involves the titration of sedative and an-
algesic drugs by intensive care unit (ICU) nurses using a
standardized algorithm and sedation assessment scale, most
commonly to achieve patient-targeted light sedation [7].
Analgesia-base sedation aims to achieve adequeate anal-
gesia while avoiding the use of sedative drugs [14].
Prioritization of analgesia is important due to the high
prevalence of pain and discomfort in the critically ill, which
can manifest as agitation. Lastly, continuous intravenous
drug infusions [12] permit more stable plasma concentra-
tions, which may facilitate sedation control compared to
intermittent dosing; however, continuous infusions can lead
to drug accumulation if not titrated closely.
The most recent Society of Critical Care Medicine (SCCM)
guidelines [17] recommend protocolized sedation or daily
sedation interruption to achieve light sedation in mechanic-
ally ventilated ICU patients. These guidelines, however, are
based on traditional pair-wise meta-analytic techniques,
which only compare two interventions at a time (e.g., daily
interruption vs. usual care). Given the growing number of
clinical trials and sedation strategies in use, we propose a
synthesis of existing data using network meta-analysis
(NMA), a novel statistical approach enabling both direct and
indirect comparisons in a multi-treatment analytical frame-
work [18–20]. This powerful statistical tool will allow the de-
termination of the relative efficacy and safety of interventions
that may or may not have been previously compared head-
to-head in randomized controlled trials.
Methods/design
This review protocol was prepared using the Preferred
Reporting Items for Systematic Review and Meta-Analyses
Protocol (PRISMA-P) guidelines [21]. We completed the
PRISMA-P checklist (Additional file 1). The protocol for
this review has been registered using the PROSPERO
International Prospective Register of Systematic Reviews
(CRD42016037480).
Data sources and search strategy
Team leaders LB, BH, and LR created a preliminary
search strategy (Additional file 2) with an experienced
senior information specialist. Prior to execution of the
search, a second senior information specialist reviewed
the strategy using the Peer Review for Electronic Search
Strategies (PRESS) template [22, 23]. The following elec-
tronic databases will be searched from1980 to March
2016: Ovid MEDLINE, Ovid MEDLINE In-Process and
Other Non-Indexed Citations, CINAHL, Embase Classic
+Embase, PsycINFO, and Web of Science. We will not
apply a language restriction. We will use a validated ran-
domized controlled trial filter and perform a separate
search for published systematic reviews and protocols in
the Cochrane Library and PROSPERO. We will form a
grey literature search using sources listed in the Canad-
ian Agency for Drugs and Technologies in Health’s
(CADTH) Grey Matters [24]. We will search for unpub-
lished and ongoing trials on the International Clinical
Trials Registry Platform (http://apps.who.int/trialsearch).
We will search the reference lists of relevant articles and
systematic reviews for studies not identified through
electronic searches. To avoid duplicate study selection,
we will compare author names and affiliations, as well as
study characteristics, and where uncertainty remains, we
will contact corresponding authors for clarification.
Study eligibility criteria
We will include randomized controlled trials, including
those using open-label and quasi-randomized (i.e.,
quasi-random method of allocation such as alternation)
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designs. We will include studies that evaluate any sed-
ation strategy in mechanically ventilated adults.
Population
Our population of interest is mechanically ventilated,
critically ill adults aged 16 years and older and treated in
any type of ICU (e.g., burn, cardiac, medical, surgical,
trauma, or mixed) or high acuity unit (e.g., high depend-
ency, step-up, step-down units).
Intervention
We will include trials that evaluate any sedation adminis-
tration strategy in mechanically ventilated adults. Ex-
pected interventions include (1) daily sedation
interruption (i.e., daily cessation of sedative, and on oc-
casion analgesic drugs), (2) protocolized sedation (i.e.,
drug titration by ICU nurses using standardized algo-
rithm and assessment tools to targeted patient sedation
level), (3) analgesia-based sedation (i.e., opioid managed
analgesia, with minimal or no sedative use), (4) intermit-
tent dosing (i.e., bolus dosing, commonl in long acting
drugs), (5) continuous dosing (i.e., uninterrupted intra-
venous dosing, common in short acting drugs), and (6)
volatile gases(i.e., volatile anaesthetic agents for sed-
ation). No restrictions will be placed on study selection
based on drug class, dose, route or duration of admin-
istration. Each intervention will have an individual
node in the analytical network (Fig. 1) and additional
interventions not specified above will be considered
should their studies meet inclusion criteria.
Comparators
NMA, an extension of the traditional meta-analytic tech-
nique, enables comparisons of multiple interventions based
on both direct and indirect evidence [19, 20, 25]. This novel
statistical approach will permit the consideration of
any trial evaluating any sedation strategies, whether
compared to each other or to usual care. Descriptions
of usual care will be extracted verbatim from included
studies to ensure similarities and differences are ap-
propriately reflected in the network structure used to
perform NMA.
Outcomes
Our primary outcome is the duration of invasive mech-
anical ventilation, defined as the time (in days) from in-
tubation to successful extubation, without requirement
of re-intubation (or ventilator support in the case of
tracheostomy) for a minimum of 24 h. The duration of
mechanical ventilation is the primary outcome for most
ICU sedation trials.
Secondary outcomes include the following: hospital
and ICU length of stay, time to first extubation, trache-
ostomy, reintubation, mortality, total sedative and opioid
exposure (using midazolam and fentanyl equivalents, re-
spectively), use of physical restraints, health-related
Fig. 1 Interventions eligible for network meta-analysis. Lines reflect comparisons that may exist between treatments. What comparisons have been studied
will be established through identified and included studies. Availability of outcomes can also impact network structure. Clinical experts have guided the
network refinement
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quality of life, and adverse events (e.g., accidental re-
moval of endotracheal tube or catheter, incidence of de-
lirium, and cardiac events (e.g., ST elevation myocardial
infarction (STEMI) or non-STEMI)). As mortality may
be defined at various time points, we will extract all re-
ported mortality outcomes and create subgroups where
needed for descriptive and analytical purposes.
Screening and data extraction
Two authors (LB, MG) will independently screen search
results against eligibility criteria to identify relevant tri-
als. Prior to screening, we will perform a calibration ex-
ercise by piloting the screening tool on a sample of ten
studies to ensure consistency in the application of eligi-
bility criteria. References will be organized using the ref-
erence management software package EndNote (X7
edition, Thomson Reuters, available at http://endnote.-
com/). We will examine the full text of any title or ab-
stract selected by either author to determine
study inclusion eligibility; in the event of a disagreement,
an independent arbiter (LR) will be consulted. Reasons
for study exclusion will be documented in the notes
field of EndNote. We will report the search strategy and
study selection process using a PRISMA flow diagram
[26].
We will divide data extraction among pairs of authors
(SK/SM, NA/MG, DW/IE). Each member of the author
pair will independently extract data using a standardized
electronic form that was developed by two authors (BH,
MG) in Microsoft Excel version 14.6.2 (Microsoft Cor-
poration, Seattle, WA, USA). The extraction form will
be piloted on five studies to ensure its capture of all rele-
vant data (MG, LB). We will extract data related to study
design, setting, patient characteristics (e.g., age, gender,
severity of illness score, reason for ICU admission),
study interventions, co-interventions potentially affect-
ing duration of mechanical ventilation (e.g., spontaneous
breathing trials), and stated outcomes of interest.
In the event of missing or unclear data, we will contact
study authors directly. Any discrepancies between data
extractors will be resolved through discussion with an
independent arbiter (LB).
Risk of bias assessment
Each data extractor will be responsible for assessing the
risk of bias of their allocated studies, and a third author
(LR) will confirm the final assessment, where necessary.
We will use a domain-based evaluation for risk of bias
assessment, as recommended by the Cochrane Collabor-
ation [27]. The domains include the following: (1) ran-
dom sequence generation (i.e., selection bias); (2)
allocation concealment (i.e., selection bias); (3) blinding
of participants and personnel (i.e., performance bias); (4)
blinding of outcomes assessment (i.e., detection bias); (5)
incomplete outcome data (i.e., attrition bias); (6) select-
ive reporting; and (7) other bias (e.g., study source of
funding). Lack of blinding will not be considered to con-
fer a high risk of bias for objective endpoints such as
mortality because the process of blinding is unlikely to
influence results.
For each domain, we will assess the risk of bias as
“low,” “high,” or “unclear.” Unclear risk will be assigned
for a domain if insufficient detail is reported and cannot
be obtained from study authors, or if what happened in
the study is known, but its contribution to the risk of
bias is unknown or unclear. After the assignment of risk
of bias, studies will be categorized as follows:
1. Low risk: all domains are considered to be at “low”
risk of bias;
2. High risk: one or more domains are considered to
be at “high” risk of bias; and
3. Unclear risk: one or more domain(s) have “unclear”
risk of bias (and no domain at high risk of bias).
Approach to evidence synthesis
In the NMA, each intervention will have its own node
(Fig. 1). If we encounter combined interventions, the re-
search team will be consulted to determine the best ap-
proach for analysis.
Members of the research team will inspect the charac-
teristics of included studies to assess their clinical and
methodological homogeneity. We will review the distri-
bution of potential effect modifiers across studies to de-
termine the validity of the assumptions of homogeneity
and similarity; [28] these modifiers will likely relate to
patient demographics (e.g., age, gender), eligibility cri-
teria (e.g., concomitant medication use), and study de-
sign (e.g., blinding, duration of follow-up). For
comparisons in the network where a minimum of two
studies is available, we will also perform conventional
pair-wise meta-analyses using a random-effects model,
and derive estimates of between - study heterogeneity of
treatment effects (with I2 > 50 % to be considered indica-
tive of potential importance) [29]. These assessments
will permit judgments about whether sufficient homo-
geneity exists within comparisons in the treatment net-
work. If homogeneity is established, we will progress to
performing the planned NMA.
We will perform NMA within a Bayesian framework,
assuming a common heterogeneity parameter across all
comparisons, and accounting for correlations in multi-
arm studies. Analyses will be performed using WinBUGS
software [30] (version 1.4.3, MRC Biostatistics Unit,
Cambridge, UK) (http://www.mrc-bsu.cam.ac.uk/software/
bugs/the-bugs-project-winbugs/) through well-established
methods [31, 32]. Continuous and binary outcomes will be
expressed in terms of mean differences and odds ratios,
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respectively, with corresponding 95 % confidence intervals
[33–35]. Surface Under the Cumulative Ranking (SUCRA)
curve estimates will also be provided [32].
Model adequacy of fit will be evaluated through compari-
son of the posterior deviance with the number of uncon-
strained data points (i.e., the total number of intervention
arms across studies) [35], and adequacy of fit will be
deemed present when these quantities are approximately
equal. Both fixed - and random-effects consistency models
will be run, and their fit will be examined via comparison of
the Deviance Information Criterion (DIC), which penalizes
model fit for complexity (note, lower values indicate better
models) [36]. A difference of five points or more will be
considered indicative of an important difference. We will fit
inconsistency models and compare their DIC values with
those of consistency models to detect inconsistency. If de-
tected, variations in individual study characteristics will be
explored as a potential cause, as will the need for additional
statistical considerations such as meta-regression. Model
convergence will be assessed using established methods in-
cluding Gelman-Rubin diagnostics and inspection of Monte
Carlo errors [35].
Subgroup and sensitivity analyses
We will explore subgroup and/or meta-regression analyses
to address the impact of covariates on our findings in
order to establish their robustness. If sufficient information
is identified, we will perform subgroup analyses to deter-
mine if our findings are influenced by (1) drug class (e.g.,
short acting such as propofol vs. long-acting such as benzo-
diazepines) and (2) type of ICU population (e.g., medical vs.
surgical). We will conduct sensitivity analyses excluding
studies with high risk of bias and involving alternative
geometries of the network. Examples of potential refor-
mulations of the network include consideration of co-
interventions known to shorten the duration of mech-
anical ventilation (e.g., weaning protocols).
Reporting of review findings
We will adhere to recommendations from the PRISMA-
NMA extension statement on NMA for reporting our
review findings [37]. We will include recommended
graphical approaches such as forest plots, league tables,
and rank-o-grams [32]. We will provide a summary of
the geometries of the networks to provide insight for fu-
ture sedation-analgesia trials in mechanically ventilated,
critically ill adults.
Dissemination of findings
We will use the knowledge-to-action framework, which
emphasizes the successful implementation of research
evidence into practice in two phases: (1) knowledge cre-
ation and (2) action. We will seek input from our know-
ledge users and affiliated organizations for knowledge
translation opportunities. We will communicate the
findings of this review via a one-page summary tailored
to specific audiences (e.g., patients and family mem-
bers, clinicians, researchers, policy makers), presenta-
tions delivered at local, national, and international
forums, and publications in peer-reviewed journals. We
will hold an end-of-project workshop where key stake-
holders will further discuss findings, identify research
gaps, and develop a knowledge translation plan to assist
with adoption of our findings.
Discussion
Several sedation administration strategies have been devel-
oped to reduce oversedation and duration of mechanical
ventilation in critically ill adults. Current critical care guide-
lines recommend the use of daily sedation interruption or
protocolized sedation to achieve targeted light sedation
[17]. Although these recommendations are based on a
number of trials and systematic reviews, they have yielded
mixed results [5, 7, 10, 13, 38–54]. Given the use of add-
itional strategies that have not yet been compared directly
(i.e., head-to-head) in clinical trials, we believe the NMA
approach has the potential to identify the strategy that most
effectively and safely avoids unnecesary days of mechanical
ventilation. Despite the strengths of the NMA approach,
our study may face certain limitations, such as the rec-
onciliation of different endpoints (e.g., duration of
follow-up and mortality measurements) and how to
analyze more complex case mixes (e.g., mixed vs. specific
ICU patient populations). This data synthesis will none-
theless allow comparisons of all available sedation strat-
egies for mechanically ventilated, critically ill adults,
thus providing clinicians, researchers, and professional
societies alike with clarity regarding the relative efficacy
and safety of available interventions.
Registration
This systematic review is registered with PROSPERO, an




Additional file 1: Preferred Reporting Items for Systematic Review and
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search strategy, including all queried databases, search parameters, and
key words. (DOCX 118 kb)
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